Optomed (OPTOMED) Q1 2025 earnings summary

Executive summary

• Revenue grew 20.9% year-over-year in Q1 2025 to EUR 4.0 million, led by Devices segment growth of 71.5% and steady Software performance.

• Devices segment revenue surged 71.5%, driven by strong US sales and Aurora AEYE adoption.

• Software segment posted 2.4% growth, with healthcare gains partly offset by non-healthcare declines.

• Gross margin improved to 67.0% from 66.5% year-over-year, reflecting favorable product mix and operational efficiency.

• Cash and cash equivalents at period end were EUR 9.7 million, supporting a robust financial position.

Financial highlights

• Q1 2025 revenue: EUR 4.0 million, up 20.9% year-over-year; Devices: EUR 1.5 million (+71.5%); Software: EUR 2.5 million (+2.4%).

• Gross profit: EUR 2.7 million (+21.7%); Gross margin: 67.0% (up from 66.5%).

• Adjusted EBITDA: EUR -0.7 million, margin improved to -18.3% from -19.5%.

• Net loss: EUR -1.6 million, down from EUR -1.1 million year-over-year; EPS: EUR -0.08.

• Cash flow from operating activities: EUR 0.4 million, up from EUR -0.5 million.

Outlook and guidance

• Full year 2025 revenue expected to grow strongly compared to 2024; outlook remains unchanged.

• Growth supported by increased adoption of AI-powered screening, new partnerships, and product innovation.

• Uncertainties include timing and size of large deals, market dynamics, and geopolitical factors.